These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 33128207)

  • 21. Busulfan Pharmacokinetics and Precision Dosing: Are Patients with Fanconi Anemia Different?
    Mehta PA; Emoto C; Fukuda T; Seyboth B; Teusink-Cross A; Davies SM; Wilhelm J; Fuller K; Vinks AA; Boulad F
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2416-2421. PubMed ID: 31326610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of glutathione S-transferase genetic polymorphisms on busulfan pharmacokinetics and veno-occlusive disease in hematopoietic stem cell transplantation: A meta-analysis.
    Kim MG; Kwak A; Choi B; Ji E; Oh JM; Kim K
    Basic Clin Pharmacol Toxicol; 2019 Jun; 124(6):691-703. PubMed ID: 30511436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intra-individual Pharmacokinetic Variability of Intravenous Busulfan in Hematopoietic Stem Cell-Transplanted Children.
    Marsit H; Philippe M; Neely M; Rushing T; Bertrand Y; Ducher M; Leclerc V; Guitton J; Bleyzac N; Goutelle S
    Clin Pharmacokinet; 2020 Aug; 59(8):1049-1061. PubMed ID: 32157629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients.
    Zwaveling J; Press RR; Bredius RG; van Derstraaten TR; den Hartigh J; Bartelink IH; Boelens JJ; Guchelaar HJ
    Ther Drug Monit; 2008 Aug; 30(4):504-10. PubMed ID: 18641537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients.
    Booth BP; Rahman A; Dagher R; Griebel D; Lennon S; Fuller D; Sahajwalla C; Mehta M; Gobburu JV
    J Clin Pharmacol; 2007 Jan; 47(1):101-11. PubMed ID: 17192508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation.
    Wall DA; Chan KW; Nieder ML; Hayashi RJ; Yeager AM; Kadota R; Przepiorka D; Mezzi K; Kletzel M;
    Pediatr Blood Cancer; 2010 Feb; 54(2):291-8. PubMed ID: 19743300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation.
    Tran H; Petropoulos D; Worth L; Mullen CA; Madden T; Andersson B; Choroszy M; Nguyen J; Webb SK; Chan KW
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):805-12. PubMed ID: 15505611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.
    Trame MN; Bergstrand M; Karlsson MO; Boos J; Hempel G
    Clin Cancer Res; 2011 Nov; 17(21):6867-77. PubMed ID: 21918171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of a Test Dose Strategy for Pharmacokinetically-Guided Busulfan Dosing for Hematopoietic Stem Cell Transplantation.
    Davis JM; Ivanova A; Chung Y; Shaw JR; Rao KV; Ptachcinski JR; Sharf AA; Serody JS; Armistead PM; Wood WA; Coghill JM; Jamieson KJ; Vincent BG; Riches ML; Shea TC; Alexander MD
    Biol Blood Marrow Transplant; 2019 Feb; 25(2):391-397. PubMed ID: 30244102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation.
    Takama H; Tanaka H; Nakashima D; Ueda R; Takaue Y
    Bone Marrow Transplant; 2006 Feb; 37(4):345-51. PubMed ID: 16400337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of genetic variants GSTA1 and CYP39A1 and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation.
    ten Brink MH; van Bavel T; Swen JJ; van der Straaten T; Bredius RG; Lankester AC; Zwaveling J; Guchelaar HJ
    Pharmacogenomics; 2013 Nov; 14(14):1683-90. PubMed ID: 24192117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.
    Rhee SJ; Lee JW; Yu KS; Hong KT; Choi JY; Hong CR; Park KD; Shin HY; Song SH; Kang HJ; Lee H
    Am J Hematol; 2017 Jul; 92(7):607-613. PubMed ID: 28370238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
    Zwaveling J; den Hartigh J; Lankester AC; Guchelaar HJ; Egeler RM; Bredius RG
    Anticancer Drugs; 2006 Oct; 17(9):1099-105. PubMed ID: 17001185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
    Ansari M; Théoret Y; Rezgui MA; Peters C; Mezziani S; Desjean C; Vachon MF; Champagne MA; Duval M; Krajinovic M; Bittencourt H;
    Ther Drug Monit; 2014 Feb; 36(1):93-9. PubMed ID: 24061446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Individualizing oral busulfan dose after using a test dose in patients undergoing hematopoietic stem cell transplantation: pharmacokinetic characterization.
    Effting C; de Moraes Arantes A; Queiroz Labre LV; Carneiro WJ; de Oliveira Neto JR; Bariani C; Rodrigues CR; Rodrigues AR; Cunha LC
    Ther Drug Monit; 2015 Feb; 37(1):66-70. PubMed ID: 25588069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted-dose of busulfan: Higher risk of sinusoidal obstructive syndrome observed with systemic exposure dose above 5000 µMol⸱min. A historically controlled clinical trial.
    Esteves I; Santos FPS; Ribeiro AAF; Seber A; Sugawara EK; Sobrinho JJDN; Barros JC; Oliveira JSR; Fernandes JF; Hamerschlak N; Andersson BS; de Lima M; Kerbauy FR
    Hematol Oncol; 2020 Dec; 38(5):773-781. PubMed ID: 32779746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation.
    Kim SD; Lee JH; Hur EH; Lee JH; Kim DY; Lim SN; Choi Y; Lim HS; Bae KS; Noh GJ; Yun SC; Han SB; Lee KH
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1222-30. PubMed ID: 21215809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
    Schechter T; Finkelstein Y; Doyle J; Verjee Z; Moretti M; Koren G; Dupuis LL
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):307-14. PubMed ID: 17317584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A simple dosing scheme for intravenous busulfan based on retrospective population pharmacokinetic analysis in korean patients.
    Choe S; Kim G; Lim HS; Cho SH; Ghim JL; Jung JA; Kim UJ; Noh G; Bae KS; Lee D
    Korean J Physiol Pharmacol; 2012 Aug; 16(4):273-80. PubMed ID: 22915993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of GST gene polymorphisms on busulfan pharmacokinetics in children.
    Ansari M; Lauzon-Joset JF; Vachon MF; Duval M; Théoret Y; Champagne MA; Krajinovic M
    Bone Marrow Transplant; 2010 Feb; 45(2):261-7. PubMed ID: 19584821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.